

2023 Current Procedural Terminology (CPT) New, Revised and Deleted CPT Codes for Oncology

This resource is a summary of the coding changes. For full details and guidelines, please refer to the 2023 American Medical Association CPT Professional Edition.

New CPT® Codes

Evaluation and Management Codes

Prolonged Services

99418 Prolonged inpatient or observation evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time

Pathology and Laboratory Services

Genomic Sequencing Procedures and other Molecular Multianalyte Assays

81441 Inherited bone marrow failure syndromes (IBMFS) (eg, Fanconi anemia, dyskeratosis congenita, Diamond Blackfan anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, congenital amegakaryocytic thrombocytopenia) sequence analysis panel, must include sequencing of at least 30 genes, including BRCA2, BRIP1, DKC1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, GATA1, GATA2, MPL, NHP2, NOP10, PALB2, RAD51C, RPL11, RPL35A, RPL5, RPS10, RPS19, RPS24, RPS26, RPS7, SBDS, TERT, and TINF2

81449 Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; **RNA analysis**

81451 Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1, NRAS), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; **RNA analysis**

81456 Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS,

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; **RNA analysis**

Propriety Laboratory Analysis Codes

0285U Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score

0287U Oncology (thyroid), DNA and mRNA, next-generation sequencing analysis of 112 genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic prediction of cancer recurrence, reported as a categorical risk result (low, intermediate, high)

0288U Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score

0295U Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score

0296U Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing of at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy

0297U Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification

0298U Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification

0299U Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification

0300U Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

0306U Oncology (minimal residual disease [MRD]), next generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD

0307U Oncology (minimal residual disease [MRD]), next generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD

0313U Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)

0314U Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)

0315U Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B)

0317U Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm generated evaluation reported as decreased or increased risk for lung cancer

0324U Oncology (ovarian), spheroid cell culture, 4-drug panel (carboplatin, doxorubicin, gemcitabine, paclitaxel), tumor chemotherapy response prediction for each drug

0325U Oncology (ovarian), spheroid cell culture, poly (ADP-ribose) polymerase (PARP) inhibitors (niraparib, olaparib, rucaparib, velparib), tumor response prediction for each drug

0326U Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden

0329U Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

0331U Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alterations

0332U Oncology (pan-tumor), genetic profiling of 8 DNA regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint–inhibitor therapy

0333U Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm reported as normal or abnormal result

0334U Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden

0337U Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood

0338U Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker–expressing cells, peripheral blood

0339U Oncology (prostate), mRNA expression profiling ofHOXC6 andDLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high grade cancer

0340U Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient’s tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate

0342U Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA199, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

0343U Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer

Vaccine Administration

0003A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA/LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; *third dose*. Reported with 91300.

0004A booster dose. Reported with CPT code 91300.

0051A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA/LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose.

0052A second dose

0053A third dose

0054A booster dose

0071A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA/LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose

0072A second dose

0073A third dose

0074A booster dose

Category II and III codes

Category II codes are used to record performance measurement. Category III codes are temporary codes assigned for emerging technology, services, procedures, and paradigms. Category II and III codes facilitate data collections and are not assigned relative value; therefore, these codes are not reimbursable.

0735T Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

0738T Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)

0739T Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation

0743T Bone strength and fracture risk using finite element analysis of functional data and bone mineral density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and BMD and classification of any vertebral fractures, with overall fracture-risk assessment, interpretation and report

0749T Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD, interpretation and report;

0750T with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD

0781T Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi

0782T unilateral mainstem bronchus

Digital Pathology (NEW)

Digital pathology enables the acquisition, management, and interpretation of pathology information generated from digitized glass microscope slides. The slides are scanned by clinical staff, and the captured images are used for digital examination. The digitization of the glass microscope slides allows for remote examination by the pathologist and/or in conjunction with the use of artificial intelligence algorithms. These codes may be reported in addition to Category I codes when the digitization procedure is performed and reported with the Category I code for the primary service. These codes should not be reported solely for archival or educational purposes, for developing a database for training or validation of AI algorithms, or for clinical conference presentations.

0751T-0755T Digitization of glass microscope slides, surgical pathology, gross and microscopic examination for levels II-VI respectively. Use in conjunction with CPT codes 88302-88309 respectively.

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

0761T Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each additional single antibody stain procedure. Use in conjunction with CPT code 88341.

0762T Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure. Use with CPT code 88344

0763T Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual. Use in conjunction with CPT code 88360.

Modifiers

93 Synchronous Telemedicine Service Rendered Via Telephone or Other Real-Time Interactive Audio-only Telecommunications System: Defined as real-time interaction between a physician or other qualified healthcare professional and a patient who is located away at a distant site from the physician or other qualified health care professional. The totality of the communication between the patient and the other qualified healthcare professional during the course of the service must be sufficient to meet the key components and/or requirements of the same service as when rendered via a face-to-face interaction.

Appendix S – Artificial Intelligence Taxonomy for Medical Services and Procedures

This new appendix section provides guidance on the emerging technology of artificial intelligence (AI) applications use in three categories: assistive, augmentative, and autonomous. The information provided is not all-inclusive and cannot be fully defined by one product, procedure, or service. The classification into one of the three categories is based on the clinical procedure or service and work performed by the machine.

Assistive: The machine detects clinical data without analyzing. The work still requires the physician/QHP to interpret and report the data. Example: computer aided detection (CAD) imaging

Augmentative: The machine analyzes and/or quantifies data in a clinically meaningful way. The work still requires the physician/QHP to interpret and report the data. Example: Continuous glucose monitoring

Autonomous: The machine independently interprets and reports data into clinically meaningful conclusions without physician/QHP input. Example: retinal imaging

Revised CPT® Codes

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

Evaluation and Management Codes

Observation Services

CPT® codes for Hospital Observation Services 99217-99226 have been deleted. These services should be reported with the revised CPT® codes for Hospital Inpatient and Observation Care Services (99221-99239). For more information regarding these changes, see the ASCO resources for the 2023 Evaluation and Management Changes on the [Coding and Reimbursement page](#) of ASCO Practice Central

Consultation Codes

CPT® code 99241, 99251 for outpatient and inpatient consultation services have been deleted. To report a consultation service with straightforward medical decision making, use CPT® codes 99242, 99252. For more information, see the ASCO resource “[2023 Evaluation and Management Changes: Consultations](#)”.

Prolonged Services

CPT® codes 99354-99357 for direct patient contact except with office and other outpatient services have been removed to report prolonged services with direct patient contact, use CPT® codes 99417 and 99418.

CPT code 99417 has been revised with the deletion of “office and” to include all outpatient evaluation and management services.

CPT codes 99446-99451 for interprofessional telephone/Internet/electronic health record assessment and management have been revised to include “qualified healthcare professional” in addition to physician as the consultative provider.

CPT code 99495-99496 for moderate level transitional care management includes revised language which clarifies the complexity required is related to the level of medical decision making.

Radiology

CPT® code 78830 for tomographic (SPECT) radiopharmaceutical localization of tumor with concurrently acquired computed tomography (CT) transmission scan, single day revised to include single area *or acquisition*.

CPT® codes 78831, 78832 for tomographic (SPECT) radiopharmaceutical localization of tumor with concurrently acquired computed tomography (CT) transmission scan, single day revised to include a minimum 2 areas *or separate acquisitions (eg lung ventilation and perfusion)*, or single area *or acquisition* over 2 or more days.

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

Genomic Sequencing Procedures

CPT codes 81445, 81450, 81455 are updated to reflect work done by a combined DNA and RNA analysis or DNA analysis performed separately, as previously the work was defined as “DNA analysis and RNA analysis when performed.” [See new CPT codes 81449, 81451, 81456](#) for RNA analysis using a separate method.

Propriety Laboratory Analysis Codes

0016M Oncology (bladder), mRNA, microarray gene expression profiling has been revised to include the requirement of profiling of 219 genes, an increase from 209 genes.

0022U targeted genomic sequence panel, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapie(s) to consider now includes the term *cholangiocarcinoma* in addition to non-small cell lung neoplasia and allows for 1-23 genes.

0090U Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes by utilizing formalin-fixed paraffin-embedded tissue has revised language to change the example language from “indeterminate” to “intermediate.”

0229U BCAT1 (Branched chain amino acid transaminase 1), IKZF1 (KAROS) family zinc finger 1 promoter methylation analysis has revised the description to include “and” instead of “or” to require analysis of both genes.

Remote Therapeutic Monitoring Services

Example language was removed for CPT codes 98975, 98976, and 98977 (Remote therapeutic monitoring) indicating “respiratory system” and “musculoskeletal status.”

Deleted CPT Codes

Propriety Laboratory Analysis (PLA) Codes

0012U Germline disorders, gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood, report of specific gene rearrangement(s)

0013U Oncology (solid organ neoplasia), gene rearrangement detection by whole genome next-generation sequencing, DNA, fresh or frozen tissue or cells, report of specific gene rearrangement(s)

0014U Hematology (hematolymphoid neoplasia), gene rearrangement detection by whole genome next generation sequencing, DNA, whole blood or bone marrow, report of specific gene rearrangement(s)

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

0056U Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)

0208U Oncology (medullary thyroid carcinoma), mRNA, gene expression analysis of 108 genes, utilizing fine needle aspirate, algorithm reported as positive or negative for medullary thyroid carcinoma

CPT Copyright 2022 American Medical Association. All rights reserved.
CPT® is a registered trademark of the American Medical Association

© American Society of Clinical Oncology | www.asco.org

ASCO[®]
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER